
浏览全部资源
扫码关注微信
纸质出版日期:2014
移动端阅览
胡玲, 苏雷, 张迎舟, 等. 银杏叶提取物注射液对肺癌化疗患者血液高凝状态的影响[J]. 中国实验方剂学杂志, 2014,20(19):194-197.
HU Ling, SU Lei, ZHANG Ying-zhou, et al. Improvement of Hypercoagulable State by Extract of Ginkgo Biloba Leaves Injection in Lung Cancer Patients Undergoing Chemotherapy[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(19): 194-197.
胡玲, 苏雷, 张迎舟, 等. 银杏叶提取物注射液对肺癌化疗患者血液高凝状态的影响[J]. 中国实验方剂学杂志, 2014,20(19):194-197. DOI: 10.13422/j.cnki.syfjx.2014190194.
HU Ling, SU Lei, ZHANG Ying-zhou, et al. Improvement of Hypercoagulable State by Extract of Ginkgo Biloba Leaves Injection in Lung Cancer Patients Undergoing Chemotherapy[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(19): 194-197. DOI: 10.13422/j.cnki.syfjx.2014190194.
目的:观察银杏叶提取物注射液对肺癌化疗患者微循环和血液流变学的改善作用。方法:100例肺癌化疗患者通过分层随机按数字表法分组法分为银杏叶提取物注射液组与低分子肝素钠组各50例,另设25例健康对照组。肺癌患者均采用一线化疗方案进行治疗,低分子肝素钠组采用肝素钠注射液,70~80 U·kg-1,分2次静脉滴注。银杏叶提取物注射液组采用银杏叶提取物注射液,20 mL/次,静脉滴注,1次/d。两组1个疗程均为10 d,间隔2 d,进行下1个疗程,共2个疗程。检测治疗前后血浆纤维蛋白原(Fib),D-二聚体(D-D)、血小板计数(PLT)和血小板聚集率(MPAR);检测治疗前后血液流变学指标。结果:肺癌患者治疗前Fib,D-D,PLT水平均明显高于健康对照组(P<0.01);银杏提取物注射液组治疗后Fib,D-D,MPV,MPAR水平低于低分子肝素钠辅组(P<0.01);银杏提取物注射液组治疗后全血黏度(高切、低切)、全血还原黏度(高切、低切)、血浆黏度、红细胞压积和血沉的改善均优于低分子肝素钠组(P<0.01);性别和病理因素对疗效影响不大,肿瘤的转移对疗效的影响有统计学意义,未发生转移的疗效好于已经转移者(P<0.05);银杏提取物注射液组累计不良反应发生率为12%,低于低分子肝素钠组的40%(P<0.01)。结论:银杏叶提取物注射液对肺癌患者的血液高凝状态有明显改善作用,对未发生转移的肺癌更好,临床使用安全。
Objective: To investigate the effect of the extract of ginkgo biloba leaves injection (EGBLI) on microcirculation and hemorheology in patients with lung cancer undergoing chemotherapy. Method: One hundred patients with lung cancer undergoing chemotherapy were divided into EGBLI group and heparin sodium injection (HIS) group of 50 patients each by a stratified random sampling method
and 25 healthy subjects were assigned to a healthy control group. Patients with lung cancer received first-line chemotherapy. Patients in HIS group received 70-80 units/kg/day heparin sodium injection (iv drip
twice daily). Patients in EGBLI group received 20 mL extract of ginkgo biloba leaves injection (iv drip
once daily). The patients received two 10-day periods of treatment separated by 2 days without treatment. Plasma fibrinogen (Fib)
D-dimer (D-D)
platelets (PLT) and maximum platelet aggregation rate (MPAR) and hemodynamic indexes were detected before and after treatment. Result: The levels of Fib
D-D and PLT in lung cancer patients were obviously higher than those in healthy subjects (P<0.01). The levels of Fib
D-D
MPV and MPAR after treatment in EGBLI group were lower than those in HIS group (P<0.01). The better improvement of blood viscosity (high shear
low shear)
whole blood reductive viscosity (high shear
low shear)
plasma viscosity
hematokrit and erythrocyte sedimentation rate were found in EGBLI group as comparied with in HIS group (P<0.01). No significant impact on effective rate of gender and pathological factors were found. Significant higer clinical effective rate were found in patients with tumor metastasis than that with no umor metastasis (P<0.05). The cumulative adverse reactions rate in EGBLI group was 12%
which was lower than 40% in HIS group (P<0.01). Conclusion: There was significant improvement of hypercoagulable state in lung cancer patients by extract of ginkgo biloba leaves injection. Besides
it is better and safe for lung cancer patient with no tumor metastatic.
0
浏览量
4
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621